Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -5.01 is 93% above its 5-year average of -71.00, near the high end of its 5-year range (-311.99–-4.13).
30.08% above its 12-month average of -7.16.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -1.08.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 15 comparable quarters.
EARNINGS PER SHARE (EPS)
-5.01
EARNINGS PER SHARE (EPS) AVG TTM
-7.16
EARNINGS PER SHARE (EPS) AVG 3Y
-89.38
EARNINGS PER SHARE (EPS) AVG 5Y
-71.00
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+30.08%
CURRENT VS 3Y AVG
+94.39%
CURRENT VS 5Y AVG
+92.94%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Cingulate Inc.
Market Cap
$65.12M
Earnings Per Share (EPS)
-5.01
TTM Avg
-7.16
3Y Avg
-89.38
5Y Avg
-71.00
Market Cap
$65.81M
Earnings Per Share (EPS)
-55.66
TTM Avg
-39.81
3Y Avg
-97.72
5Y Avg
-154.19
Market Cap
$64.06M
Earnings Per Share (EPS)
N/A
TTM Avg
-0.02
3Y Avg
-0.02
5Y Avg
-0.01
Market Cap
$62.78M
Earnings Per Share (EPS)
-1.09
TTM Avg
-1.47
3Y Avg
-0.85
5Y Avg
-0.92
Market Cap
$63.95M
Earnings Per Share (EPS)
-2.02
TTM Avg
-7.29
3Y Avg
-26.82
5Y Avg
-38.33
Market Cap
$68.43M
Earnings Per Share (EPS)
2.68
TTM Avg
-1.38
3Y Avg
-6.44
5Y Avg
-7.90
Market Cap
$69.33M
Earnings Per Share (EPS)
-0.08
TTM Avg
0.13
3Y Avg
-0.17
5Y Avg
-0.10
Market Cap
$68.12M
Earnings Per Share (EPS)
-0.19
TTM Avg
-0.10
3Y Avg
-0.67
5Y Avg
-1.24
Market Cap
$70.09M
Earnings Per Share (EPS)
-0.33
TTM Avg
-1.03
3Y Avg
-28.69
5Y Avg
-510.63
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cingulate Inc. (CING) | $65.12M | -5.01 | -7.16 | -89.38 | -71.00 |
| Gossamer Bio, Inc. (GOSS)vs › | $65.81M | -55.66 | -39.81 | -97.72 | -154.19 |
| Alps Group Inc (ALPS)vs › | $64.06M | N/A | -0.02 | -0.02 | -0.01 |
| InterCure Ltd. (INCR)vs › | $62.78M | -1.09 | -1.47 | -0.85 | -0.92 |
| Kalaris Therapeutics Inc (KLRS)vs › | $63.95M | -2.02 | -7.29 | -26.82 | -38.33 |
| Fortress Biotech, Inc. (FBIO)vs › | $68.43M | 2.68 | -1.38 | -6.44 | -7.90 |
| Champions Oncology, Inc. (CSBR)vs › | $69.33M | -0.08 | 0.13 | -0.17 | -0.10 |
| Heron Therapeutics, Inc. (HRTX)vs › | $68.12M | -0.19 | -0.10 | -0.67 | -1.24 |
| iBio, Inc. (IBIO)vs › | $70.09M | -0.33 | -1.03 | -28.69 | -510.63 |
| Adicet Bio, Inc. (ACET)vs › | $60.39M | N/A | -19.12 | -29.60 | -38.42 |
Trailing EPS (TTM)
$-5.01
Forward EPS (Est.)
$-2.13
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -4.13 |
| 2024-12-31 | -10.20 |
| 2023-12-31 | -311.99 |
| 2022-12-31 | -31.20 |
| 2021-12-31 | -55.80 |
| 2020-12-31 | -12.70 |
| 2019-12-31 | -242.89 |
